[go: up one dir, main page]

CN1321149A - 托拉沙得新晶体变型ⅲ - Google Patents

托拉沙得新晶体变型ⅲ Download PDF

Info

Publication number
CN1321149A
CN1321149A CN99811710A CN99811710A CN1321149A CN 1321149 A CN1321149 A CN 1321149A CN 99811710 A CN99811710 A CN 99811710A CN 99811710 A CN99811710 A CN 99811710A CN 1321149 A CN1321149 A CN 1321149A
Authority
CN
China
Prior art keywords
torasemide
iii
crystal modification
torsaemide
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN99811710A
Other languages
English (en)
Other versions
CN1125049C (zh
Inventor
D·菲里克
M·杜米克
A·达尼罗夫斯基
B·科莱匹克
I·菲斯特里克
M·欧里希克
J·霍瓦特米库尔希克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliva Farmaceutika dd
Original Assignee
Pliva Farmaceutska Industrija dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10946825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1321149(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pliva Farmaceutska Industrija dd filed Critical Pliva Farmaceutska Industrija dd
Publication of CN1321149A publication Critical patent/CN1321149A/zh
Application granted granted Critical
Publication of CN1125049C publication Critical patent/CN1125049C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Liquid Crystal (AREA)
  • Liquid Crystal Substances (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

本发明涉及托拉沙得新晶体变型Ⅲ的特征,涉及在添加或不添加晶种的情况下,通过用无机酸或有机酸受控制地酸化碱性托拉沙得溶液来制备托拉沙得新晶体变型Ⅲ的方法,及其用作制备托拉沙得晶体变型Ⅰ和药用托拉沙得盐的原料,以及涉及含这种托拉沙得新晶体变型Ⅲ的药物形态。

Description

托拉沙得新晶体变型Ⅲ
本发明涉及N-(1-甲基乙基氨基羰基)-4-(3-甲基-苯基氨基)-3-吡啶磺酰胺(本文中称为“托拉沙得新晶体变型)，本发明尤其涉及托拉沙得新晶体变型Ⅲ及其制备方法，及其作为制备托拉沙得晶体变型Ⅰ和作为制备药用托拉沙得盐的原料，以及包含作为活性成分的所述托拉沙得新晶体变型Ⅲ的药物形态。
拉托沙得是一种具有药理性质的化合物，已公开在德国专利2516025(实施例71)中。作为亨勒的利尿剂，它可用作防止心脏或心脏组织受到因与局部供血不足有关的新陈代谢或电解质紊乱而引起的损伤的药剂，可用来治疗血栓形成、心绞痛、气喘、高血压、肾水肿、肺水肿、一级和二级醛甾酮过多症、Bartter氏综合症、肿瘤、青光眼、使眼压下降、急性或慢性支气管类、还可用来治疗因外伤引起的大脑水肿、局部供血不足、脑震荡、转移或癫痫发作以及治疗因变态反应引起的鼻部感染。
一种物质能以一种以上晶体形态存在的现象称为同质多晶现象，这些不同晶型称为“多晶变型”或“多晶型物”。一般来说，同质多晶现象受物质分子改变构型的可能性或形成不同分子间的作用或分子内相互作用的可能性的影响，尤其是受氢键的影响，同质多晶现象反映出不同多晶型物的晶格中的不同的原子排列。已经发现了几种有机化合物呈同质多晶现象。药物中有约70％巴比妥酸盐、60％磺酰胺和60％甾族化合物已发现有同质多晶现象，而且市场上有约50％所述种类的药物不是以它们最稳定的形态销售的(T.Laird,“精细化学工业中的化学进展及演化、原理和实践教程”(Chemical Development andScale-up in the Fine Chemical Industry,Principles andPractices,Course Manual)”,Scientific Update,WyvernCattage,1996)。
物质的不同多晶型物具有不同的晶格能量，因此，在固态时它们显示出不同的物理性质(如形态、密度、熔点、颜色、稳定性、溶解速率、研磨可能性、成粒作用、压紧性等)，在药剂中这些性质会影响各种药物形态的制备、稳定性、溶解性和生物利用度，从而影响药物的作用。
因为一种有关同质多晶现象的完整知识是阐明整个药物研制过程的关键观察结果的先决条件，因此，药物的同质多晶现象是学科专家们研究的课题[J.Haleblian,W.McCrone,“制药科学杂志(J.Pharm.Sci.)”58(1969)911；L.Borka,(Pharm.Acta Helv.)66(1991)16；M.Kuhnert-Brandsttter,“药物学(Pharmazie)”51(1996)443；H.G.Brittain.“制药科学杂志(J.Pharm.Sci)”86(1997)405；W.H.Streng,DDT2(1997)415；K.Yoshii,“化学制药公报(Chem.Pham.Bull.)”45(1997)338，等]。于是，在决定药物以固体状态及有关剂量大小、稳定性、溶解作用和预期的作用进行生产时，必须确定所有存在的固体形态(在市场上可找到一些计算机程序，例如作为《Cerius 2》程序的模块《Polymorph》,MSI Inc.,USA)，以及确定每种固体形态的稳定性、溶解作用以及热力学性质。只有在确定这些因素的基础上才能为药物配方的研制选出适用的晶型。
现从大量的研究工作中只选出几项研究作介绍。Gordon等人的美国专利4476248保护了一种布洛芬新晶型及其制备方法；Bunnell等人的欧洲专利733635保护了一种奥氮平新晶型及其制备方法以及含这种新晶型药物奥氮平的药物配方；R.B.Gandhi等人的欧洲专利749969保护了从stavudine Ⅰ、Ⅱ和Ⅲ形态的混合物中制备stavudine多晶型Ⅰ的新方法；A.Caron等人的欧洲专利708103保护了一种依具沙坦新晶型及其制备方法以及含该晶型的药物配方。
众所周知[如从晶体学学报(Acta Cryst.)B34(1978),2659-2662和“晶体学学报(Acta Cryst.)”B34(1978),1304-1310可知]托拉沙得可呈两种具有不同单晶胞参数的晶体变型，这已由单晶的X射线衍射实验得到证实。通过缓慢蒸发出托拉沙得在石油醚/乙醇混合物中的溶液的溶剂，在除去溶剂时可同时形成两种晶体变型。晶体变型Ⅰ的熔点为169℃，呈P21/c(棱晶)空间群的单斜晶型，而晶体变型Ⅱ的熔点为162℃，呈P2/n(薄片)空间群的单斜晶型。此外，Iyakuhin Kenkyu 25(1994),734-750中对晶体变型Ⅰ熔点为169.22℃作了说明。
根据德国专利2516025中的实施例71，得到的托拉沙得是熔点为163-164℃的晶型。
在美国专利4743693和美国再颁专利34580或美国专利4822807和美国再颁专利34672中，公开了通过向托拉沙得的不稳定变型在水中的悬浮体添加催化量(1％)托拉沙得的稳定变型Ⅰ，并在室温至90℃搅拌混合物3小时至14天，而由托拉沙得的不稳定变型Ⅱ制成托拉沙得的稳定变型Ⅰ的方法。美国专利4743693和美国再颁专利34580公开的托拉沙得的稳定变型Ⅰ(单斜、P21/c空间群)的熔点为162℃，托拉沙得的不稳定变型Ⅱ(单斜，P2/n空间群)的熔点为169℃，这一结果与“晶体学学报(Acta Cryst.)”B34(1978),2659-2662，“晶体学学报(Acta Cryst.)”B34(1978)1304-1310和Iyakuhin Kenkyu25(1994),734-750中所述结果相反。
在美国专利4822807的摘要中，作者们确定托拉沙得的稳定多晶型物Ⅰ的熔点为162℃，托拉沙得的不稳定多晶型物Ⅱ的熔点为169℃，而所述专利的权利要求项中说明的每一种多晶型物的熔点与此不同，即多晶型物Ⅰ的熔点为169℃而多晶型物Ⅱ的熔点为162℃。
在美国再颁专利34672的摘要中，作者们确定纯的托拉沙得变型Ⅰ的熔点为162℃，托拉沙得变型Ⅱ的熔点为169℃，而权利要求项中纯的多晶型物Ⅰ的熔点为159-161.5℃，不稳定的多晶型物Ⅱ的熔点为约157.5-约160℃。
已经出乎意料地发现，在0-35℃温度下，在添加或不添加晶种的情况下，通过用无机酸或有机酸在15分钟-25小时内受控制地酸化托拉沙得碱性溶液可制得托拉沙得新晶体变型Ⅲ。
根据本发明方法的托拉沙得碱性溶液是指托拉沙得合成的初始反应混合物的碱性提取液，任何一种托拉沙得晶体变型Ⅰ、Ⅱ或Ⅲ的碱性溶液或任何一种托拉沙得晶体变型Ⅰ、Ⅱ或Ⅲ的相互混合物的碱性溶液。
在本发明方法中，可采用氢氧化锂、氢氧化钠和氢氧化钾的水溶液以及碳酸钠和碳酸钾的水溶液来制备托拉沙得变型的碱性溶液。
可用无机酸如盐酸、硫酸、磷酸和硝酸以及用有机酸如甲酸、乙酸、丙酸、草酸、酒石酸、甲磺酸和对甲苯磺酸来酸化本发明的托拉沙得碱性溶液。
作为本发明方法中的晶种，可采用一种同结构物质的晶体粉末，特别是托拉沙得晶体变型Ⅲ的晶体粉末。
还业已发现，采用本发明方法托拉沙得不会发生分解，通过本发明方法，可能存在于托拉沙得合成的初始反应混合物的碱性萃取液中或存在于托拉沙得变型Ⅰ、Ⅱ或Ⅲ中的杂质会进入碱中，即可得到化学纯的托拉沙得晶体变型Ⅲ。
此外，还业已发现，托拉沙得新晶体变型Ⅲ在通常贮存条件和高湿度条件下是稳定的，这就意味着，它既不会转变成托拉沙得的不稳定变型Ⅱ，也不会转变成托拉沙得的稳定变型Ⅰ。
托拉沙得新晶体变型Ⅲ的特征X射线粉末衍射图是由PHILIPS PW3710衍射仪以Cu X-射线[λ(CuKα1)=1.54046和λ(Cukα2)=1.54439]对托拉沙得新晶体变型Ⅲ的粉末试样作X衍射测定得到的。于是得到的晶格面间的特征间距(以《d》表示；单位为埃)以及与之相对应的特征相对强度(以《I/I0》表示，％)的结果列于表1中。表1
变型Ⅲ
d() I/I0(％)
    15.3898     2.8
    12.5973     5.4
    11.4565     5.8
    9.7973     69.8
    9.5493     76.6
    8.6802     28.5
    8.2371     100.0
    7.6351     10.2
    7.3356     13.0
    6.9759     1.2
    6.5351     10.0
    6.3240     7.9
    6.1985     4.5
    5.9521     0.6
    5.6237     24.4
    5.5623     29.7
    5.4040     19.6
    5.1119     10.3
    4.8738     22.7
    4.7865     46.9
    4.6986     45.7
    4.5985     17.9
    4.4602     24.7
    4.3405     90.0
    4.2552     20.7
    4.1829     19.9
    4.0768     19.9
    3.9377     47.1
    3.8659     29.3
    3.8429     35.3
    3.7801     42.8
    3.7248     11.9
    3.6239     31.7
    3.5556     20.5
    3.4825     7.8
    3.4130     8.1
    3.3055     15.5
    3.2298     8.2
    3.1786     10.7
    3.1278     5.6
    3.0699     7.1
    3.0078     17.5
    2.9549     5.1
    2.9056     4.3
    2.8541     1.8
    2.7686     13.9
    2.6988     5.7
    2.6610     6.3
    2.6293     7.3
    2.5549     3.7
    2.5236     2.0
    2.4485     5.3
    2.4161     6.7
    2.3671     2.0
    2.3133     3.6
    2.2788     7.6
    2.2312     3.4
    2.1852     6.2
    2.1468     3.0
    2.0957     4.7
    2.0617     4.1
    2.0273     3.3
    1.9896     3.1
    1.9688     4.1
    1.9274     2.6
    1.8853     2.7
    1.7931     2.1
    1.7449     1.0
    1.7169     1.8
    1.6512     1.0
    1.6122     0.8
    1.5601     0.8
    1.5320     0.3
    1.5057     0.5
    1.4521     0.3
    1.3773     0.6
此外，借助四圆PHILIPS PW 1100/Stoe&Cie衍射仪的Mo X-射线[λ(moKα=0.71073]记录托拉沙得新晶体变型Ⅲ单晶衍射，将得到的单晶胞基本结晶学数据与托拉沙得晶型Ⅰ和Ⅱ的文献数据[“晶体学学报(Acta Cryst.)”B34(1978),2659-2662和“晶体学学报(ActaCryst.)”B34(1978)1304-1310]作比较，结果显示，该晶型完全是托拉沙得的一种新晶体变型Ⅲ。
托拉沙得晶体变型Ⅰ、Ⅱ和新晶体变型Ⅲ的基本结晶学数据(单晶衍射)列于表2中。表2
    参数                      托拉沙得的晶体变型
    Ⅰ     Ⅱ     Ⅲ
    晶体结构     单斜晶系     单斜晶系 单斜晶系
    空间群     P 21/c     P 2/n     P 21/c
    a()     13.308     20.446     11.430
    b()     8.223     11.615     19.090
    c()     31.970     16.877     16.695
    β(°)     107.01     108.90     93.903
    V(3)     3345.5     3791.9     3634.7
    Z     4×2     4×2     4×2
根据本发明方法制备的托拉沙得新晶体变型Ⅲ可通过常规方法转变为托拉沙得晶体变型Ⅰ，即它可用作制备已知的托拉沙得晶体变型Ⅰ的原料。
根据本发明制备的托拉沙得新晶体变型Ⅲ可通过常规方法转变成药用托拉沙得盐。
托拉沙得新晶体变型Ⅲ在水中和人工肠液中的溶解特性(USP23)与托拉沙得的已知晶体变型Ⅰ和Ⅱ在相同液体中的溶解特性作比较，结果显示，有明显的差别。
托拉沙得新晶体变型Ⅲ在人工胃液中的IDR(固有溶解速率)超过1毫克/(平方厘米·分钟)，由此可说明该晶型具有相当好的生物利用度。
根据本发明方法制备的托拉沙得新晶体变型Ⅲ具有棱晶特性，呈可流动的晶体粉末状，这种晶型具有流动性，即处于“自由流动”形态，其中不会发生静电荷积聚。
根据本发明方法制备的托拉沙得新晶型Ⅲ可用作利尿剂以及可用作防止心脏或心脏组织受到因与局部供血不足有关的新陈代谢或电解质紊乱而引起的损伤的药剂，可用来治疗血栓形成、心绞痛、气喘、高血压、肾水肿、肺水肿、一级和二级醛甾酮过多症、Bartter氏综合症、肿瘤、青光眼、使眼压下降、急性或慢性支气管炎、还可用来治疗因外伤引起的大脑水肿、局部供血不足、脑震荡、转移或癫痫发作以及治疗因变态反应引起的鼻部感染。
本发明还涉及药物形态，例如包含作为活性成分的、与药用的一种或多种药用添加剂如糖、淀粉、淀粉衍生物、纤维素、纤维素衍生物、脱模剂以及防粘剂和流动性调节剂相混合的托拉沙得新晶型Ⅲ的片剂。当采用托拉沙得新晶型Ⅲ来制备各种形态的药物时，也可采用以水处理如用水粒化的步骤。
用于本发明方法的起始物料，即托拉沙得合成的初始反应混合物的碱性提取液可按照德国专利2516025制备，而托拉沙得变型Ⅰ和Ⅱ可按照“晶体学学报(Acta Cryst.)”B34(1978),1304-1310制备。
下面将通过实施例对本发明作说明，但决不是对本发明的限制。
实施例1
技术上纯净的托拉沙得新晶型Ⅲ：
按照德国专利2516025制备的托拉沙得合成的反应混合物的初始碱性提取液(1000毫升)，在添加1.4克托拉沙得晶体变型Ⅲ的情况下以10％乙酸水溶液酸化。在室温下搅拌该悬浮液90分钟。经吸滤分离出晶体，以1升软化水洗涤，然后在50℃的真空干燥箱中干燥3小时。可得到125克熔点为162-165℃的托拉沙得晶体变型Ⅲ。
所得晶体试样的X-射线粉末衍射图与托拉沙得新晶体变型Ⅲ相符。按照高压液相色谱法(HPLC)测得的托拉沙得含量＞99％。
实施例2
将按照实施例1制得的托拉沙得晶体变型Ⅲ(1000克)溶于10倍量的5％氢氧化钾水溶液中，并于20℃，在添加10克托拉沙得晶体变型Ⅲ的情况下，用5％盐酸水溶液酸化所得溶液。在20℃下搅拌该悬浮液120分钟。经吸滤分离出晶体，以4升软化水洗涤之，然后在50℃的真空干燥箱中干燥3小时。得到961克熔点为165℃的托拉沙得变型Ⅲ。
所得晶体试样的X-射线粉末衍射图与托拉沙得晶体变型Ⅲ相符，按照HPLC方法测得的托拉沙得含量＞99.5％，即相当于化学纯托拉沙得。
实施例3
将按照“晶体学学报(Acta Cryst.)”B34(1978),1304-1310制得的托拉沙得晶体变型Ⅰ(1.00克)溶于10倍量的10％碳酸钠水溶液中，并于15℃、在添加0.10克托拉沙得变型Ⅲ的情况下，用5％硫酸水溶液酸化所得溶液。在15℃下搅拌该悬浮液120分钟。经吸滤分离出晶体，以4毫升软化水洗涤之，然后在50℃的真空干燥箱中干燥3小时。得到0.95克熔点为165-166℃的托拉沙得晶体变型Ⅲ。
所得晶体试样的X-射线粉末衍射图与托拉沙得晶体变型Ⅲ相符。按照HPLC方法测得的托拉沙得含量＞99.5％，即相当于化学纯托拉沙得。
实施例4
将按照“晶体学学报(Acta Cryst.)”B34(1978),1304-1310制得的托拉沙得晶体变型Ⅱ(1.00克)溶于10倍量的10％碳酸钾水溶液中，然后于15℃、在添加0.10克托拉沙得变型Ⅲ的情况下，用5％硝酸水溶液酸化所得溶液。在15℃下搅拌该悬浮液120分钟。经吸滤分离出晶体，以4毫升软化水洗涤之，然后在50℃的真空干燥箱中干燥3小时。得到0.96克熔点为164-166℃的托拉沙得晶体变型Ⅲ。
所得晶体试样的X-射线粉末衍射图与托拉沙得晶体变型Ⅲ相符。按照HPLC方法测得的托拉沙得含量＞99.5％，即相当于化学纯托拉沙得。
实施例5
将按照“晶体学学报(Acta Cryst.)”B34(1978),1304-1310制备的托拉沙得晶体变型Ⅰ和Ⅱ的混合物溶于10倍量的10％氢氧化锂水溶液中，然后于室温、在添加0.10克托拉沙得变型Ⅲ的情况下，用5％磷酸水溶液酸化所得溶液。在15℃下搅拌该悬浮液240分钟。经吸滤分离出晶体，以4毫升软化水洗涤之，然后在50℃的真空干燥箱中干燥3小时。得到0.97克熔点为165-166℃的托拉沙得晶体变型Ⅲ。
所得晶体试样的X-射线粉末衍射图与托拉沙得晶体变型Ⅲ相符。按照HPLC方法测得的托拉沙得含量＞99.5％，即相当于化学纯托拉沙得。
实施例6
将分别按照“晶体学学报(Acta Cryst.)”B34(1978),1304-1310和实施例1制得的托拉沙得晶体变型Ⅰ和Ⅲ的混合物(1.00克)溶于10倍量的5％氢氧化钾水溶液中，然后于30℃、在添加0.10克托拉沙得变型Ⅲ的情况下，用10％酒石酸水溶液酸化所得溶液。在30℃下搅拌该悬浮液180分钟。经吸滤分离出晶体，以4毫升软化水洗涤之，然后在50℃的真空干燥箱中干燥3小时。得到0.93克熔点为164-166℃的托拉沙得晶体变型Ⅲ。
所得晶体试样的X-射线粉末衍射图与托拉沙得晶体变型Ⅲ相符。按照HPLC方法测得的托拉沙得含量＞99.5％，即相当于化学纯托拉沙得。
实施例7
将分别按照“晶体学学报(Acta Cryst.)”B34(1978),1304-1310和实施例1制得的托拉沙得晶体变型Ⅱ和Ⅲ的混合物(1.00克)溶于10倍量的5％氢氧化钠水溶液中，然后于35℃、在添加0.10克托拉沙得变型Ⅲ的情况下，用5％丙酸水溶液酸化所得溶液。在35℃下搅拌该悬浮液90分钟。经吸滤分离出晶体，用4毫升软化水洗涤之，然后在50℃的真空干燥箱中干燥3小时。得到0.87克熔点为165℃的托拉沙得晶体变型Ⅲ。
所得晶体试样的X-射线粉末衍射图与托拉沙得晶体变型Ⅲ相符。按照HPLC方法测得的托拉沙得含量＞99.5％，即相当于化学纯托拉沙得。
实施例8
将按照“晶体学学报(Acta Cryst.)”B34(1978),1304-1310和实施例1制得的托拉沙得晶体变型Ⅰ、Ⅱ和Ⅲ的混合物(1.00克)溶于10倍量的10％碳酸钠水溶液中，然后于25℃、在添加0.10克托拉沙得变型Ⅲ的情况下，用5％对甲苯磺酸水溶液酸化所得溶液。在25℃下搅拌该悬浮液60分钟。经吸滤分离出晶体，用4毫升软化水洗涤之，并在50℃的真空干燥箱中干燥3小时。得到0.93克熔点为164-166℃的托拉沙得晶体变型Ⅲ。
所得晶体试样的X-射线粉末衍射图与托拉沙得晶体变型Ⅲ相符。按照HPLC方法测得的托拉沙得含量＞99.5％，即相当于化学纯托拉沙得。
实施例9
将按“晶体学学报(Acta Cryst.)”B34(1978),1304-1310制得的托拉沙得晶体变型Ⅰ(1.00克)溶于10倍量的10％碳酸钾水溶液中，然后在15℃，用10％乙酸水溶液逐步酸化所得溶液，与此同时逐步使混合物温度降至0℃，在该温度下搅拌该悬浮液25小时。经吸滤分离出晶体，用4毫升软化水洗涤之，然后在50℃真空干燥箱中干燥3小时。得到0.94克熔点为164-166℃的托拉沙得晶体变型Ⅲ。
所得晶体试样的X-射线粉末衍射图与托拉沙得晶体变型Ⅲ相符。按照HPLC方法测得的托拉沙得含量＞99.5％，即相当于化学纯托拉沙得。
实施例10
2.5毫克片剂的制备：
以常规方法使托拉沙得晶体变型Ⅲ与乳糖和玉米淀粉相混合，然后用水粒化，并干燥和过筛(粒料1)。将胶态二氧化硅与硬脂酸镁相混合、过筛并混入粒料1中。然后以常规方法将混合物压成片。对于生产100000片片剂所需的物料如下：
托拉沙得晶体变型Ⅲ                        0.25千克
乳糖(Lactose Extra Fine Crystal HMS)   6.05千克
玉米淀粉(Starch)                       1.60千克
胶态二氧化硅(Aerosil200)               60.00克
硬脂酸镁                                  40.00克
重蒸馏水                                  1.20千克
实施例11
100毫克片剂的制备：
以常规方法使托拉沙得晶体变型Ⅲ与乳糖和玉米淀粉及一部分硬脂酸镁相混合。对该混合物进行挤压并过筛以达到所要求的粒度和粒度分布(粒料1)。使胶态二氧化硅与硬脂酸镁相混合、过筛，并混入粒料1中。然后以常规方法将混合物压成片。对于生产100000片片剂所需的物料如下：
托拉沙得晶体变型Ⅲ                        10.0千克
乳糖(Lactose Extra Fine Crystal HMS)   2.0千克
玉米淀粉(Starch)                       7.7千克
胶态二氧化硅(Aerosil200)               0.2千克
硬脂酸镁                                  0.1千克
实施例12
将按照“晶体学学报(Acta Cryst.)”B34(1978),1304-1310和实施例1制得的托拉沙得的微晶变型Ⅰ、Ⅱ和Ⅲ置于37℃的水中和人工肠液中进行溶解试验(USP23)，试验结果列于表3和表4中。表3：托拉沙得在水中的溶解试验(USP23)(37℃,50rpm,1000毫升)
    分钟                        ％溶解托拉沙得
    变型Ⅰ     变型Ⅱ     变型Ⅲ
    0     0     0     0
    10     6.7     15.1     15.6
    20     13.0     27.8     28.1
    30     18.5     39.2     37.7
    40     23.5     48.8     43.6
    50     28.5     56.3     48.5
    60     32.8     65.1     51.1
表4：托拉沙得在人工肠液中的溶解试验(USP23)(37℃,50rpm,pH7.5,
1000毫升)
    分钟                     ％溶解托拉沙得
    变型Ⅰ     变型Ⅱ     变型Ⅲ
    0     0     0     0
    10     29.4     73.3     41.0
    20     40.5     92.6     59.8
    30     48.4     95.5     70.2
    40     54.2     96.8     77.6
    50     59.2     96.3     82.5
    60     65.0     98.2     88.7
表3所列数据已绘成曲线，见图1。表4所列数据已绘成曲线，见图2。

Claims (16)

1．托拉沙得新晶体变型Ⅲ，其特征在于其试样的特征X-射线粉末衍射图是以下列晶格面之间的间距表示的：     托拉沙得新晶体变型Ⅲ     d()     15.3898     12.5973     11.4565     9.7973     9.5493     8.6802     8.2371     7.6351     7.3356     6.9759     6.5351     6.3240     6.1985     5.9521     5.6237     5.5623     5.4040     5.1119     4.8738     4.7865     4.6986     4.5985     4.4602     4.3405     4.2552     4.1829     4.0768     3.9377     3.8659
    3.8429     3.7801     3.7248     3.6239     3.5556     3.4825     3.4130     3.3055     3.2298     3.1786     3.1278     3.0699     3.0078     2.9549     2.9056     2.8541     2.7686     2.6988     2.6610     2.6293     2.5549     2.5236     2.4485     2.4161     2.3671     2.3133     2.2788     2.2312     2.1852     2.1468     2.0957     2.0617     2.0273     1.9896     1.9688     1.9274     1.8853     1.7931
    1.7449     1.7169     1.6512     1.6122     1.5601     1.5320     1.5057     1.4521     1.3773
2．根据权利要求1的托拉沙得新晶体变型Ⅲ，其特征在于根据其试样单晶体的X-射线衍射，托拉沙得新晶体变型Ⅲ是以下列基本结晶学数据表示的：     参数     托拉沙得的新晶体变型     晶体结构     单斜晶系     空间群     P 21/c     a()     11.430     b()     19.090     c()     16.695     β(°)     93.903     V(3)     3634.7     Z     4×2
3．根据权利要求1-2的托拉沙得新晶体变型Ⅲ，其特征在于它是化学纯的。
4．根据权利要求1-3的托拉沙得新晶体变型Ⅲ，其特征在于它不含水。
5．根据权利要求1-4的托拉沙得新晶体变型Ⅲ，其特征在于它不含溶剂。
6．制备根据权利要求1-5的托拉沙得新晶体变型Ⅲ的方法，其特征在于碱性托拉沙得溶液于0-35℃、在添加或不添加晶种的情况下，以无机酸或有机酸在15分钟-25小时内受控制地酸化。
7．根据权利要求1-6的托拉沙得新晶体变型Ⅲ的制备方法，其特征在于采用托拉沙得合成的初始反应混合物的碱性提取液作为碱性托拉沙得溶液。
8．根据权利要求1-6的托拉沙得新晶体变型Ⅲ的制备方法，其特征在于采用任何一种托拉沙得晶体变型Ⅰ、Ⅱ或Ⅲ的碱性溶液，或采用任何一种托拉沙得晶体变型Ⅰ、Ⅱ或Ⅲ的相互混合物的碱性溶液作为碱性托拉沙得溶液。
9．根据权利要求1-8的方法，其特征在于采用氢氧化锂、氢氧化钠和氢氧化钾的水溶液以及碳酸钠和碳酸钾的水溶液来制备碱性托拉沙得溶液。
10．根据权利要求1-9的方法，其特征在于采用无机酸如盐酸、硫酸、磷酸或硝酸或者是有机酸如甲酸、乙酸、丙酸、草酸、酒石酸、甲磺酸或对甲苯磺酸来实施酸化。
11．根据权利要求1-10的方法，其特征在于采用一种同晶物质的晶体粉末作为晶种，最优选为托拉沙得晶体变型Ⅲ的晶体粉末。
12．根据权利要求1-11的托拉沙得新晶体变型Ⅲ，其特征在于它用作制备托拉沙得晶体变型Ⅰ的原料。
13．根据权利要求1-11的托拉沙得新晶体变型Ⅲ，其特征在于它用作制备药用托拉沙得盐的原料。
14．根据权利要求1-11的托拉沙得新晶体变型Ⅲ，其特征在于它以托拉沙得的形态用作利尿剂，用作防止心脏或心脏组织受到因与局部供血不足有关的新陈代谢或电解质紊乱而引起的损伤的药剂，用来治疗血栓形成、心绞痛、气喘、高血压、肾水肿、肺水肿、一级和二级醛甾酮过多症、Batter氏综合症、肿瘤、青光眼、使眼压下降、急性或慢性支气管炎，还可用来治疗因外伤引起的大脑水肿、局部供血不足、脑震荡、转移或癫痫发作以及治疗因变态反应引起的鼻部发炎。
15．一种药物形态，其特征在于该药物包含作为活性成分的、与药用的一种或多种载体、添加剂或稀释剂相混合的根据权利要求1-11的托拉沙得晶体变型Ⅲ。
16．根据权利要求15的一种药物形态，其特征在于它是片剂。
CN99811710A 1998-10-02 1999-10-01 托拉沙得新晶体变型n Expired - Fee Related CN1125049C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HRP980532A 1998-10-02
HR980532A HRP980532B1 (en) 1998-10-02 1998-10-02 Novel crystalline torasemide modification

Publications (2)

Publication Number Publication Date
CN1321149A true CN1321149A (zh) 2001-11-07
CN1125049C CN1125049C (zh) 2003-10-22

Family

ID=10946825

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99811710A Expired - Fee Related CN1125049C (zh) 1998-10-02 1999-10-01 托拉沙得新晶体变型n

Country Status (32)

Country Link
US (5) US6399637B1 (zh)
EP (1) EP1117643B1 (zh)
JP (1) JP2002526532A (zh)
KR (1) KR100437307B1 (zh)
CN (1) CN1125049C (zh)
AT (1) ATE286024T1 (zh)
AU (1) AU759291B2 (zh)
BG (1) BG105485A (zh)
BR (1) BR9915018A (zh)
CA (1) CA2345789A1 (zh)
CZ (1) CZ20011031A3 (zh)
DE (2) DE29924789U1 (zh)
DK (1) DK1117643T3 (zh)
EE (1) EE04341B1 (zh)
ES (1) ES2237158T3 (zh)
HK (1) HK1040250B (zh)
HR (1) HRP980532B1 (zh)
HU (1) HUP0104009A3 (zh)
ID (1) ID29931A (zh)
IL (1) IL142150A0 (zh)
NO (1) NO317107B1 (zh)
NZ (1) NZ510898A (zh)
PL (1) PL346975A1 (zh)
PT (1) PT1117643E (zh)
RU (1) RU2210569C2 (zh)
SI (1) SI1117643T1 (zh)
SK (1) SK4232001A3 (zh)
TR (1) TR200100909T2 (zh)
UA (1) UA72895C2 (zh)
WO (1) WO2000020395A1 (zh)
YU (1) YU24001A (zh)
ZA (1) ZA200102451B (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106038500A (zh) * 2016-05-26 2016-10-26 南京正科医药股份有限公司 一种托拉塞米片
CN115417810A (zh) * 2022-09-22 2022-12-02 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法
CN117486789A (zh) * 2023-12-29 2024-02-02 江西中医药大学 一种托拉塞米共晶盐及其制备方法和应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6394707B1 (en) 1997-05-08 2002-05-28 Jack Kennedy Metal Products & Buildings, Inc. Yieldable mine roof support
HRP980532B1 (en) 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
SI20816A (sl) * 1999-08-11 2002-08-31 Teva Pharmaceutical Industries Ltd. Polimorfi torsemid-a
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
HRP20000162B1 (en) * 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
HRP20000328A2 (en) * 2000-05-19 2002-02-28 Pliva Farmaceutska Ind Dionik Novel polymorph v of torasemide
IN192178B (zh) 2001-08-03 2004-03-06 Ranbaxy Lab
HRP20020603B1 (en) * 2002-07-19 2008-11-30 Pliva D.D. New process for the preparation of modification i n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide
CA2424644A1 (en) * 2003-04-07 2004-10-07 David John Mckenzie Preparation of torasemide
US20050065183A1 (en) * 2003-07-31 2005-03-24 Indranil Nandi Fexofenadine composition and process for preparing
EP1750862B1 (en) * 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
JP4406845B2 (ja) 2007-02-20 2010-02-03 トヨタ自動車株式会社 二次電池電極材の剥離剤及び該剥離剤を用いた二次電池の処理方法
EP2705843A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis
CN104370805B (zh) * 2013-08-13 2016-09-07 天津汉瑞药业有限公司 托拉塞米化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1477664A (en) * 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
US4055650A (en) * 1974-04-17 1977-10-25 A. Christiaens Societe Anonyme Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines
US4473693A (en) 1978-08-04 1984-09-25 Stewart Walter W Aminonaphthalimide dyes for intracellular labelling
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
HRP980532B1 (en) 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US6166045A (en) * 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106038500A (zh) * 2016-05-26 2016-10-26 南京正科医药股份有限公司 一种托拉塞米片
CN115417810A (zh) * 2022-09-22 2022-12-02 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法
CN117486789A (zh) * 2023-12-29 2024-02-02 江西中医药大学 一种托拉塞米共晶盐及其制备方法和应用

Also Published As

Publication number Publication date
HK1040250B (zh) 2004-03-05
EE200100194A (et) 2002-06-17
NO20011633L (no) 2001-03-30
HUP0104009A3 (en) 2002-04-29
DE29924789U1 (de) 2005-08-25
KR100437307B1 (ko) 2004-06-25
SI1117643T1 (en) 2005-06-30
ES2237158T3 (es) 2005-07-16
NZ510898A (en) 2002-10-25
SK4232001A3 (en) 2001-10-08
EP1117643B1 (en) 2004-12-29
RU2210569C2 (ru) 2003-08-20
PL346975A1 (en) 2002-03-11
CZ20011031A3 (cs) 2001-08-15
US20030055258A2 (en) 2003-03-20
UA72895C2 (uk) 2005-05-16
DK1117643T3 (da) 2005-03-29
IL142150A0 (en) 2002-03-10
ID29931A (id) 2001-10-25
EE04341B1 (et) 2004-08-16
TR200100909T2 (tr) 2001-07-23
HRP980532B1 (en) 2005-06-30
KR20010079962A (ko) 2001-08-22
ATE286024T1 (de) 2005-01-15
NO20011633D0 (no) 2001-03-30
HUP0104009A2 (hu) 2002-02-28
HK1040250A1 (zh) 2002-05-31
AU759291B2 (en) 2003-04-10
US20020147346A1 (en) 2002-10-10
HRP980532A2 (en) 2000-12-31
NO317107B1 (no) 2004-08-09
US20040229919A1 (en) 2004-11-18
US6833379B2 (en) 2004-12-21
US20070276015A1 (en) 2007-11-29
EP1117643A1 (en) 2001-07-25
US20060205951A1 (en) 2006-09-14
US6399637B1 (en) 2002-06-04
BR9915018A (pt) 2001-08-14
BG105485A (en) 2002-01-31
CA2345789A1 (en) 2000-04-13
ZA200102451B (en) 2001-09-28
DE69922977C5 (de) 2008-12-24
DE69922977D1 (de) 2005-02-03
YU24001A (sh) 2003-02-28
JP2002526532A (ja) 2002-08-20
WO2000020395A1 (en) 2000-04-13
PT1117643E (pt) 2005-05-31
CN1125049C (zh) 2003-10-22
DE69922977T2 (de) 2005-12-08
AU6224099A (en) 2000-04-26

Similar Documents

Publication Publication Date Title
CN101679218B (zh) 晶体米诺环素碱及其制备方法
CN1321149A (zh) 托拉沙得新晶体变型ⅲ
JP2023528565A (ja) Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法
RU2613555C2 (ru) Моногидратный кристалл калиевой соли фимасартана, способ его получения и содержащая его фармакологическая композиция
CN101772491A (zh) 基本不含有二聚体杂质的瑞格列奈
JP2007520546A (ja) モンテルカストナトリウムの安定な非晶質性形態
WO2016169422A1 (zh) 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
CN106458905B (zh) 贝曲西班盐及其制备方法和用途
CN101137626A (zh) 2－(3－氟－4－羟基苯基)－7－乙烯基－1,3－苯并唑－5－醇的晶形及其作为雌激素受体调节剂的用途
WO2017162139A1 (zh) 用于治疗或预防jak相关疾病药物的盐酸盐晶型及其制备方法
CN1211368C (zh) 无定形的托拉塞米变体
CN1520403A (zh) 托拉塞米的新颖多晶型物v
CN104910147B (zh) 阿哌沙班晶体及其制备方法
WO2013174035A1 (zh) 一种制备磷酸西他列汀无水晶型i的方法
CN102850333A (zh) 奥美沙坦酯晶体及其制备方法
KR102544543B1 (ko) L,d-엘도스테인의 개별적 공결정화물
KR101477155B1 (ko) 4-[2-디메틸아미노-1-(1-하이드록시사이클로헥실)에틸]페닐 4-메틸벤조에이트 하이드로클로라이드의 다형체, 이의 제조 방법 및 이의 용도
JP4842819B2 (ja) モダフィニル組成物
CN104098575A (zh) 一种盐酸依匹斯汀晶型及其制备方法和用途
HK40033890B (zh) 药学化合物、其盐类、其制剂和其制备和使用方法
HK1058203A (zh) 无定形的托拉塞米变体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee